ArticleFrontiers in pediatrics2026
Molecular epidemiology of respiratory viral infections in hospitalized children in Novosibirsk, Russia, 2021-2023.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute respiratory infections (ARIs) are among the leading global causes of morbidity and mortality in children. While viral agents of ARI are rigorously monitored, other pathogenic organisms and pathobionts - bacteria and fungi native to the host microbiome - remain largely neglected. Adenoviral types also warrant particular attention especially given the widespread use of adenoviral vector vaccines during the COVID-19 pandemic. Methods: Oro-nasal swabs collected from 1679 children under the age of 18 hospitalized in Novosibirsk, Russia between February 2021 and June 2023, were tested for the presence of nucleic acids by the diagnostic panel targeting 17 viruses, 12 bacteria and one yeast. Adenovirus-positive samples were additionally fine-typed by Sanger sequencing. Results: Overall, 79.15% of samples were positive for at least one of 17 viral pathogens, with RSV (22.87% positives) and RhV (24.54% positives) dominating the etiological structure. Oro-nasal presence for respiratory pathobionts and opportunistic pathogens was 67.96% and 11.49%, respectively. Generally, viral seasonality was typical for continental climate, with only two notable deviations: MpV absence in spring of 2022 followed by earlier December peaks in the same year; an earlier RSV maximum in October 2021 with extended circulation the next epidemic season. Overall, the epidemiology of the analyzed viruses was consistent with worldwide surveillance trends and largely stable between the two later epidemic seasons. In viral-bacterial association analysis we identified two significantly attracted pairs, in which virus is known to facilitate bacterial adherence to respiratory epithelium. Adenovirus fine-typing provided preliminary evidence that serotypes 1, 2, 3, and 7 are the most frequently detected among the typed samples, while vaccine serotype AdV-5 was identified in only two cases. Conclusion: Broad target coverage allowed for a comprehensive analysis of epidemiological patterns, highlighting a trend toward stabilization of the etiological structure to pre-pandemic levels, and allowed for prioritization of clinically relevant viral-bacterial associations. Preliminary findings in adenoviral fine-typing are consistent with global trends in serotype prevalence and help address an important gap in regional adenoviral epidemiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.